Conducting clinical trials outside the United States raises significant regulatory concerns that sponsors must evaluate before relying on foreign data to support a marketing approval submission or Investigational New Drug Application (IND) to the United States Food and Drug Administration (FDA)….
By: Foley Hoag LLP
By: Foley Hoag LLP
